Foamix Pharmaceuticals Ltd.
2 Holzman Street, Weizmann Science Park
Rehovot 7670402, Israel

April 10, 2018

BY EDGAR

Suzanne Hayes

Assistant Director

Securities and Exchange Commission

Office of Healthcare and Insurance

100 F Street, N.E.

Washington, DC 20549

Re: Foamix Pharmaceuticals Ltd.

Registration Statement on Form S-3

(File No. 333-224084)

Dear Ms. Hayes:

Pursuant to Rule 461 under the Securities Act of 1933 (the “Securities Act”), Foamix Pharmaceuticals Ltd. hereby requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange Commission so that the Registration Statement, as amended, will become effective under the Securities Act at 5:00 p.m. ET on April 12, 2018 or as soon thereafter as practicable.

We request that we be notified of such effectiveness by a telephone call to Andrea L. Nicolas of Skadden, Arps, Slate, Meagher & Flom LLP at (212) 735-3416 and that such effectiveness also be confirmed in writing.

	Very truly yours

	FOAMIX PHARMACEUTICALS LTD.

	/s/ Ilan Hadar
	By: Ilan Hadar
	Title: Chief Financial Officer

cc:	Phyllis G. Korff, Esq. Andrea L. Nicolas, Esq. Skadden, Arps, Slate, Meagher & Flom LLP Four Times Square New York, NY 10036